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SUMMARY OF AMENDMENTS 
General Response 
 
The Examiners’ Reports highlighted areas of this thesis that required clarification and 
areas well presented, and for this I would like to thank all the reviewers for their 
important suggestions and critique of the thesis. I found all phases of undertaking the 
degree of Doctor of Philosophy extremely rewarding including responding to the 
Examiners’ comments, which allowed me to further refine the work presented. Please 
note that all the misprints and grammatical errors have been corrected in the thesis 
without notification below. My responses are as follows. 
 
Specific Comments and Responses 
 
Examiner:  Professor John Patience 
 
Chapter 1: General Introduction 
Comment:  Page 2, line16 Schinckel has some excellent modeling papers that are 
relevant in defining the lysine requirements. 
Response: The relevant paper has now been cited. Referencing this paper does not 
alter the wording of the paragraph, because the paper emphasizes that greater than 1.0 
g/kg total lysine is required for finishing pigs supplemented with dietary RAC between 
80 and 120 kg in order to optimize growth rate and carcass lean yield.  
 
Chapter 2: Review of the Literature 
Comment:  Reference throughout the thesis is made to limit feeding pigs. If this is 
the case then limit feeding is another difference between US and Australian conditions 
that probably should be mentioned. 
Response:  Limit feeding is not practiced commercially in Australia. The reference 
to limit feeding in this thesis comes from the paper by Dunshea et al (2009) in which 
finishing pigs housed in individual pens were limit-fed to reflect typical energy intakes 
of commercial finisher pigs. Dunshea et al (2009) were investigating whether the 
combination of dietary RAC and betaine was additive. 
 
Comment: Define the term “available” lysine. 
Response:  At first introduction of the term “available lysine”, Section 2.5.4, p26 the 
term has been referenced as a footnote and defined in the footnote as standardized ileal 
digestibility of lysine.  
 
Comment:  Given the interest in lysine level and ractopamine level, the student 
might wish to refer to Ross et al (2011) in which studied both these factors. 
Response: I have included the following paragraph in section 2.5.4 of the Literature 
Review: “A recent study in Canada by Ross et al (2011) observed no response in ADG 
or G:F for barrows fed dietary RAC across 3 levels of standardized ileal digestible 
(SID) lysine : DE ratios of 1.73, 2.14 and 2.63 g Mcal of DE (equivalent to 0.41, 0.51 
and 0.63 g available lysine / MJ of DE). The expectation of a RAC x lysine interaction 
was not observed by Ross et al (2011) and the authors concluded that this may have 
been due to the excellent feed intakes (approximately 4.0 kg/day) providing greater than 
22g of available lysine per day on the low lysine diet. Additionally Ross et al (2011) 
argued that lysine was not limiting in this experiment as a RAC x Lys interaction was 
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not observed for any growth variable, and a 16% improvement in protein gain in RAC 
fed pigs over controls was observed.” 
 
Chapter 3: 
Comment: I do not think this is a 3 x 5 factorial experiment. 
Response: I have changed the description of the experimental design in section 
3.2.1 to read as follows: “The study involved 120 pigs (40 gilts, 40 boars and 40 boars 
immunized against GnRF) and was carried out as a randomized complete block design 
consisting of three animal types (gilts, boars and boars immunized against GnRF) and 
five RAC dose regimes [(i) 0 mg/kg, (ii) 5 mg/kg and (iii) 10 mg/kg for 28 days, (iv) 5 
mg/kg for 14 days and 10 mg/kg for 14 days (5/10 mg/kg RAC Step-up), (v) 5 mg/kg for 
28 days plus daily pST (5mg/ml) injections (Reporcin®, OzBiofarm, Victoria) for the 
last 14 days] with 8 pigs per treatment group.” 
 
Comment: The initial and final weights should be noted either in the tables as an 
experiment outcome (final weight) or in footnotes to the table so the reader knows the 
initial and final weight. 
Response: Initial and final weights have been included in Table 3.2. I have also 
included initial and final live weights in Table 5.4 and initial weights in Table 6.3.  
 
Comment: The chapter discussion and conclusion does not specifically refer back to 
the hypothesis and in this instance state that the hypothesis was not supported. 
Response: I have altered the conclusion, section 3.5 as follows: “The results of the 
study presented do not support the hypothesis that diets supplemented with RAC over a 
4-week period in single dose, step-up or single dose program with the addition of daily 
pST treatment in the final 2 weeks will improve feed efficiency as well as increase lean 
tissue deposition in boars, boars immunized against GnRF and gilts.”  
 
Chapter 4: 
Comment: These data should be analyzed statistically using repeated measures 
analysis, since numerous repeated measures were reported. 
Response: The Examiner has commented he has concerns that repeated measures 
analysis was not used in Chapter 4, 5 and 7. In response, I would argue that the use of 
repeated measures analysis in these chapters is not required. Whilst measurements such 
as live weight was obviously repeated on the experimental units at day -7, 0, 7, 14, 21, 
and 28, one considers applying repeated measures when: 
1. There is an expectation of variability of the trait to differ between treatments. In 
all studies presented the variation of the trait measured was expected to be the 
same among treatments, and only the treatment mean for the trait was expected 
to differ. 
2. The repeated measure is likely to have a correlation with the adjacent 
measurements. This may have been the case if I had presented average daily 
gain (ADG) in the following manner 0-7; 7-14, 14-21, 21-28. However I have 
presented ADG for  periods: 0 – 7; 0 – 14 and 0 – 21 which are considered  
independent estimates of the animals performance. 
Reference:  
Kaps and Lamberson (2009) Biostatistics for animal science, an introductory 
text. CAB International, Wallingford Oxon, U.K.: 405 - 431. 
Consultation with Professor Frank Dunshea. 
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Furthermore, the DXA information presented in Chapter 5 should not be analysed using 
repeated measures as each individual pig in the experiment only underwent a DXA 
measurement once (see Section 5.2.4, DXA live animal scanning). The body 
composition was determined for boars and gilts from one replicate from each dietary 
treatment at Days –1, 15 and 29, by using DXA as described by Dunshea et al. (2009). 
All pigs in the study were scanned once only. 
 
Comment: The student indicates the danger of discussing sex effects since gilts and 
boars were studied in separate experiments, and then proceeds to compare sex 
responses. This should be corrected. 
Response: In section 4.3.2, Experiment 2: Boars, I have excluded the references to 
Experiment 1: Gilts. The original paragraph was as follows: “As was seen with the 
gilts, the light initial-weight boars had a better FCR than either medium or heavy 
initial-weight boars (2.45 vs 2.58 and 2.71, respectively (P<0.001). Similar to the gilts, 
the ADFI increased with heavier pigs at the start (2954, 3153 and 3354 g/day for light, 
medium and heavy boars, respectively (P<0.001))”. The paragraph has been altered to: 
“The light initial-weight boars had a better FCR than either medium or heavy initial-
weight boars (2.45 vs 2.58 and 2.71, respectively (P<0.001). The ADFI increased with 
heavier pigs at the start (2954, 3153 and 3354 g/day for light, medium and heavy boars, 
respectively (P<0.001)).” 
 
To improve clarity of section 4.4.3, Effects of start weight and dosage level of RAC on 
feed conversion ratio, I have altered the paragraph from: “In the present studies, 
dietary RAC improved FCR in gilts (P=0.023) but not in boars (P=0.289), although it is 
difficult to compare sexes in the present experiments as the studies were carried out at 
different times.” The paragraph has been changed to: “In the present experiments, 
dietary RAC improved FCR in gilts, Experiment 1 (P=0.023), but not in boars, 
Experiment 2 (P=0.289). However and because the experiments were separate and 
carried out at different times, differences in responses to dietary RAC should be viewed 
with caution.” 
 
The intent of the discussion in section 4.4.3 was to highlight that although the boars did 
not improve FCR when fed dietary RAC in Experiment 2, the result cannot be compared 
to the significant improvement in FCR shown by gilts fed dietary RAC in Experiment 1 
because the studies were separate. I then referred to the literature to highlight that no 
sex effects had been reported in studies measuring FCR in boars and gilts fed dietary 
RAC.  
 
Comment: The explanation of no differences observed in PUN is not consistent with 
the literature, or our understanding of nitrogen metabolism in pigs. 
Response: In section 4.4.2, Effects of dosage level of RAC on Plasma urea nitrogen, 
I have altered the following explanation from: “ A possible explanation for this result 
could be that all the diets offered provided excess dietary protein (Table 4.1) for 
maximal protein deposition (King et al., 2000), and as such amino acid catabolism 
across all treatments resulted in similar levels of PUN.”, to the following explanation: 
“The fact that RAC did not alter PUN may indicate disease challenge and pigs that do 
not efficiently utilize dietary lysine, and therefore amino acid catabolism occurred 
across all treatments resulting in similar levels of PUN.”. The effect of disease is 
discussed further in Chapter 6. 
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Reference: van Heugten, E., Spears, J. W. &Coffey, M. T. (1994). The effect of dietary 
protein on performance and immune response in weanling pigs subjected to an 
inflammatory challenge. Journal of Animal Science 72(10): 2661-2669. 
 
Chapter 5 
Comment: I found this experiment perhaps a bit complex, given that the primary 
question being asked related to the adequacy of the lysine recommendations. 
Confounding the experiment with multiple levels of ractopamine seemed to detract from 
the ability to clearly answer the question and also reduced the precision of the 
experiment as well. 
Response: The complexity of the experiment was quite deliberate because the aim 
was to determine whether there were interactions between RAC dosage levels and 
dietary lysine on growth performance and carcass characteristics of finisher boars and 
gilts using dual energy X-ray absorptiometry (DXA) to measure body composition. The 
low level of lysine was chosen because it reflected commercial diets supplemented with 
RAC that were used in the Australian industry at that time. The high level of lysine was 
chosen to reflect recommendations from the literature which were primarily directed 
towards the US swine industry. 
 
Comment: Repeated measures should have been used, particularly the DXA data. 
Response:  I have addressed this issue in Chapter 4 responses (above). 
 
Comment: The methods section states that pigs were fed ad libitum but later states 
that blood samples were collected 3 hours after feeding. Please address this apparent 
discrepancy. 
Response: In section 5.2.5, Determining Plasma Urea Nitrogen (PUN) content, the 
first paragraph has been altered from: “Blood samples were obtained by jugular 
venipuncture three hours after feeding on day -2 and day 9.”, to: “Blood samples were 
obtained by jugular venipuncture three hours after the morning feed inspection on day -
2 and day 9.” 
 
Chapter 6 
Comment: Table 6.1 needs an explanation as to how the diet were prepared. 
Response: In section 6.2.2, Experimental Animals and diets, I have included the 
following sentence to explain how the five dietary lysine levels were attained: “The 
composition of the control diets was formulated to meet the specified lysine:energy 
ratios (Table 1), by blending the two extreme lysine level diets A and E in specific ratios 
to produce control diets B (25% A and 75%E), C (50% A and 50% E) and D (75% A 
and 25%E).” 
 
Comment: What is meant by the term Total available lysine in Table 6.1. 
Response: I have included in the footnotes of Table 6.1 the definition of “Available 
Lysine” and “Total Available Lysine” 
 
Comment: Specify whether the broken line model or the quadratic model was used 
to define the lysine requirement, furthermore there is no explanation of how the model, 
and the model parameters were selected in terms for example of best fit. 
Response: The broken line model was used to define the lysine requirement. I have 
reworded and included additional lines in section 6.2.6 to further explain how the 
model and the model parameters were selected. The original explanation is as follows: 
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“A break point analysis was applied to these data for ADG and FCR for each 
sex. The quadratic curves for ADG and FCR for each sex were fitted by a nonlinear 
regression computer model using GenStat 11th Edition (Payne et al., 2008).   
 
a + b.(lysine) + c.(Lysine ≥ d).(d-Lysine)) 
 
The estimates for a, b, c and d parameters were determined for each quadratic 
curve, where: 
 
a = where the graph crosses the y axis at zero 
b = (maximum gain – a) ÷ (d) 
c = same as ‘b’ 
d = lysine concentration where maximum gain occurs 
  
The model determined computed values for the parameters a, b, c and d. The 
computed values were then used to determine the maximum or minimum response for 
each trait using the straight line equation: 
 
Response of trait = a + b (lysine concentration) 
 
The computed value of d is the lysine concentration where maximum gain 
occurs, and this is also where the break point occurs on the graph. To determine the 
minimum gain, the lowest level of lysine concentration is used in the above equation.” 
 
This has been altered to: 
 
“A break point analysis was applied to these data for ADG and FCR for each sex 
without and with dietary RAC. A nonlinear regression computer model (GenStat 11th 
Edition (Payne et al., 2008) was used to determine the critical lysine value for each 
data set.  The regression model was defined as: 
 
a + b.(lysine) + c.(Lysine ≥ d).(d-Lysine)) 
 
where:  a = where the graph crosses the y axis at zero 
b = (maximum gain – a) ÷ (d) 
c = same as ‘b’ 
d = lysine concentration where maximum gain occurs 
 
Prior values of the non-linear parameters ‘a’, ‘b’, ‘c’ and ‘d’ were estimated by 
fitting each ADG and FCR data set to the model. In order to obtain the best fitting 
segmented lines the model performs iterative numerical calculations to define the prior 
values. The computer model produced a nonlinear regression analysis for the response 
trait (ADG or FCR) and estimates of the non-linear parameters and corresponding 
standard errors were obtained. The computed values for a, b, c and d were then used to 
determine the maximum or minimum response for each trait using the straight line 
equation: 
 
Response of trait = a + b (lysine concentration) 
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The computed value of d is the lysine concentration where maximum gain occurs 
(critical value), and this is also where the break point occurs on the graph. To 
determine the minimum gain, the lowest level of lysine concentration is used in the 
above equation. 
 
Comment: I would encourage the student to analyze the response to lysine in more 
biologically-based outcomes, such as g lysine/g lean tissue accretion. 
Response: I would certainly agree that the application of this type of analysis would 
have been invaluable had it been incorporated into the study, however the logistics of 
incorporating DXA scanning of live pigs or half carcasses was not possible and was 
also too expensive. DXA scanning was incorporated into studies reported in Chapter 5 
and 7 where I was able to show differences in lean tissue accretion rate when 
differences were not apparent in ADG for pigs fed dietary RAC. To this extent I have 
clearly demonstrated the value of reporting lean accretion rates over ADG. 
 
Chapter 7 
Comment: The issue of repeated measures analysis is relevant to this chapter. 
Response: I have addressed this issue in Chapter 4 responses (above). 
 
Comment: In the second experiment, is it possible that the absence of a response to 
ractopamine in boars was due to inadequate lysine? Also the quantity of added lysine 
HCL is very high; could this have been an issue as well? 
Response: The boars in the second experiment did respond to dietary RAC in the 
first 14 days, however this was expressed as a reduced ADFI rather than an improved 
ADG, the outcome being a significant (P=0.033) improvement in G:F. In this regard, I 
wonder whether the Examiner is referring to the first Experiment? If so, then I have 
proposed that lysine may have been limiting to boars in section 7.4 Discussion, p144. 
 
The quantity of Lysine HCL in the second experiment was not high. In this thesis 
addition rates of Lysine HCL for most diets was expressed as a % of the composition of 
the diet, however in Table 7.4 Lysine HCL is presented in g/kg, therefore the value of 
0.9 g/kg is equivalent to 0.09% which is lower than additional Lysine HCL in 
experiments in Chapter 4 (Table 4.1; 0.16%); Chapter 5(Table 5.1; 0.3%); Chapter 6 
(Table 6.1; 0.26%) and Chapter 7 (Table 7.1; 0.23%).  
 
Chapter 8 
Comment: More details on biopsy collection methods would be helpful. 
Response: In section 8.2 I have included the following sentences: 
“Immediately prior to tissue sampling, the pig was anaesthetised as described in section 
3.2.6 and a whole body DXA scan (Suster et al., 2004) was taken to determine fat, 
muscle and ash content. Specific to this chapter, immediately after DXA scanning, 
approximately 1 g of muscle (Gluteus Maximus) and 2 g of subcutaneous fat was taken 
from the same incision site on the hind leg. All samples were individually wrapped in 
foil and labelled: study number, date of sample, pig number. Samples were placed in 
liquid nitrogen and stored at -80ºC until required for tissue analysis.” 
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Specific Comments and Responses 
 
Examiner:  Professor Martin Sillence 
 
Declaration 
Comment 1: The author is an employee of the company that markets ractopamine. As 
such I recommend that the issue of potential conflict of interest should be addressed 
and/or declared. 
Response: I have added  the following statement to the original Declaration: “All 
experiments were planned and all results shared in full consultation with, and 
disclosure to, my supervisors Professor John Pluske and Professor Frank Dunshea” 
 
Summary: 
Comment 2: The summary is too long and should be re-written with a focus on the 
main aims and conclusions of the work as a whole body. 
Response: I disagree with the Examiner’s appraisal of the Summary. A total of 
seven separate experiments were conducted all of which required a brief description of 
experimental procedures and the main results and their significance highlighted. The 
thesis presents “a cogent description of a large body of work” and hence the Summary 
reflects the volume presented. The summary had also been read, reviewed and 
suggestions made by my supervisor, Professor John Pluske, prior to submission for 
examination. 
 
Comment 3: pIII. It is stated that RAC had no effect on ADG, but it is unclear 
whether this applies to RAC alone, RAC with pST, or both. 
Response: I have amended the sentence to include the treatment RAC+pST: “The 
results of Experiment 1 were surprising in the fact dietary RAC and RAC+pST had no 
effect on average daily gain (ADG) (P=0.543) or feed conversion ratio (FCR) 
(P=0.255) on these fast-growing, high-health-status finishing pigs.” 
 
Comment 4: p6. The American terms epinephrine and norepinephrine should be 
replaced with English terms adrenaline and noradrenaline throughout the review. 
Response: The English terms have been used throughout the thesis.  
 
Comment 5: p6. Note that noradrenaline is both a neurotransmitter and a hormone 
released from the adrenal gland. 
Response: I have altered the sentence to read as follows: “Noradrenaline is both a 
neurotransmitter molecule and a hormone that is released from the adrenal gland and 
also the nerve endings of both the central nervous and sympathetic nervous systems, 
and is biosynthesised from tyrosine.” 
 
Comment 6: p6. The term β-adrenergic is used throughout the thesis without regard to 
its precise meaning. ‘ergic’ refers specifically to a nerve, and so the term is appropriate 
when discussing ‘adrenergic nerves, or neurotransmitters’. The correct term for the 
corresponding receptors is β-adrenoceptors (β-AR), and the term for a compound such 
as ractopamine is β-adrenoceptor agonist. 
Response: The term “β-adrenergic receptors” and “β-adrenergic agonist” have 
been replaced with “β-adrenoceptors” and “β-adrenoceptor agonist” respectively 
throughout the thesis. 
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Comment 7: p12. Down regulation refers to long-term processes where there is 
significant receptor degradation and a decrease in the rate of receptor synthesis. Using 
the term desensitisation in a global sense to describe both short and long term events is 
not helpful. 
Response: I have altered the introductory paragraph in section 2.3.2, 
Desensitization of β-AR signalling, such that there is a clear distinction between the 
processes of ‘desensitisation’ and ‘down regulation’ of the β-adrenoceptors in the 
presence of a β-adrenoceptor agonist. The altered introductory paragraph is as follows: 
“Desensitisation is the reduction of response despite the continued presence of the 
stimulus. The mechanism that contributes to desensitisation involves the “uncoupling” 
of the receptors from G-protein, which is initiated in seconds to minutes of agonist 
exposure. The term down regulation refers to long-term processes and develops more 
slowly than uncoupling, taking hours to days (Mills, 2002b). Down regulation involves 
receptor degradation and a decrease in the rate of receptor synthesis. Both 
desensitisation and down regulation restricts the use of stimuli such as β-adrenoceptor 
agonists in animal production today, and research to circumvent these processes are 
discussed in section 2.6 of this review.”  
 
Comment 8: p14. The discussion of theophylline shows good evidence of critical 
thinking. It is also worth mentioning that much of the work conducted on adipose tissue 
β-AR during the early 1990’s led to erroneous conclusions based on flawed assumptions 
about sub-type selectivity in porcine tissue, of various compounds that had been used in 
the past to characterise these receptors in humans and other species.  
Response: In section 2.4.1, Lipolysis in adipose tissue, I have inserted a final 
paragraph: “Much of the work conducted on adipose tissue β-AR during the 1990s led 
to erroneous conclusions based on flawed assumptions about subtype selectivity in 
porcine tissue of the various compounds that had been used in the past to characterise 
these receptors in humans and other species (Sillence et al., 2005). β-ARs are well 
characterized in many mammalian species, however they have been difficult to define in 
porcine adipose tissue either through the adrenergic control of lipolysis (Liu et al., 
1989) or direct ligand binding experiments (Coutinho et al., 1992; Mersmann, 1992). 
Researchers have reported that porcine β-AR do not show the degree of selectivity for 
classic β-AR ligands typical of other animal species (Coutinho et al., 1992; Liang and 
Mills, 2002; Mersmann, 2002). Furthermore the radioligands that have been proved to 
be ideal for labelling β-AR in some tissues and species, in swine can profoundly 
influence the characterization of the receptor (Mersmann and McNeel, 1992).” 
 
Comment 9: p18. Use isoprenaline throughout not the American “isoproterenol” 
Response: The English terms have been used throughout the thesis. 
 
Comment 10: p18. Provide some further interpretation or explanation of the results 
cited by Ding et al (2000). How do you reconcile the decrease in β-AR number caused 
by isoprenaline in the absence of any decrease in mRNA? 
Response: I have consulted the paper by Ding et al. (2000). The following 
paragraph has been inserted in section 2.4.3, Down regulation of β-AR in adipose 
tissue: “A plausible explanation for the decrease in β-AR number caused by 
isoprenaline in the absence of any decrease in β-AR mRNA is discussed by Ding et al. 
(2000). The β-AR have cAMP response elements (CRE) in the 5′ -untranslated region 
that are stimulated by phosphorylated CRE binding proteins. The role of cAMP is to 
activate protein kinase A (see section 2.3.1), which then phosphorylates the CRE 
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binding protein. Thus, increased cAMP can increase β-AR transcription. Nothing is 
known about the function of the CRE in porcine β-AR subtypes, however, the 
intracellular concentration of cAMP is increased when porcine adipocytes are 
incubated with isoprenaline (Hu et al., 1987). Speculatively, the modest isoproterenol-
stimulated desensitization of porcine adipocyte βAR with no change in the β1AR and 
β2AR transcript concentrations may represent a relatively high rate of cAMP-
stimulated transcription and translation coupled with modest rates of receptor 
phosphorylation and sequestration from the membrane. These experiments help explain 
the lack of response recorded in many studies measuring fat deposition in pigs treated 
with dietary RAC.” 
 
Comment 13: p38. What instrument/detection system is was used for the amino acid 
analysis?   
Response: In section 3.2.3, Determining amino acid contents of each diet, I have 
included the following sentences to clarify the detection system used for the amino acid 
analysis: “Each separated amino acid was then mixed with the detection reagent 
ninhydrin and converted in a reaction loop (post-column) at 130°C to a ready 
measurable, characteristic blue violet or yellow colour. The amino acids were then 
detected by a photometer at a light of wavelength of 570 nm (or 440 nm for yellow 
proline derivatives) and through an integrated computer, a chromatogram was 
produced from which the concentration of the amino acid is determined.” 
 
Comment 14: p40. Presumably the RAC diets were specially formulated for this trial 
by adding a known quantity of RAC to a known quantity of feed? Explain why it is 
necessary to measure actual RAC content of the feed by chemical analysis. Note that 
chemical analysis is subject to error and provides an estimate of the actual 
concentration. 
Response: RAC diets were specially formulated for this trial by the addition of a 
known quantity of RAC to a known quantity of feed. It was necessary to measure actual 
RAC content (parts per million) to verify uniform distribution of RAC in the final feed.  
In section 3.2.4. I have added the following opening sentence: “In order to verify that 
RAC premix addition was uniformly distributed throughout each treatment diet at the 
expected concentration, samples from each treatment (and control) diet were taken for 
laboratory analysis of RAC concentration.” 
 
Comment 15: p42. The first paragraph should cite the relevant tables and figures that 
appear on the subsequent pages. 
Response: I have cited Table 3.2 in the first paragraph. 
 
Comment 16: p42. Define “empty body tissue” 
Response: The term has been defined in section 3.2.6, DXA live animal scanning. 
Comment 17: p48. Reproductive quality of the figures throughout the thesis is very 
poor, particularly the axis labels, which are hardly legible in my copy. 
Response: All figures checked – legibility is fine in both pdf version and Microsoft 
Word program. The unclear axis may have been a result of the printed copy. I consulted 
with Professor John Pluske in the construction and final presentation of each chapter, 
and all figures have been presented in the same format. The figures presented in 
Chapters 5 and 6 are from published papers and accepted by Animal Production 
Science.  
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Comment 18: Figures 3.1 and 3.2 could easily fit on one page. 
Response: Figures 3.1 and 3.2 are now on one page. 
 
Comment 19: p50. There appears to be a problem with the reference management 
system as the citations appear with a # symbol, a citation number and curly brackets. 
Response: This simply means that Endnote references and citations require 
updating. This has been done and should now not occur at all in the thesis. 
 
Comment 23: p54. It is unclear if the 96 pigs were 96 gilts, or 96 gilts or boars. 
Rephrase. 
Response: I have described experimental numbers in section 4.2.1 as “A total of 96 
gilts (Experiment1) and 96 boars (Experiment 2) were allocated to 12 treatments with 8 
replicates per treatment per experiment.” 
 
Comment 25: Statistics. In this chapter and all others there is no explanation of how 
means are separated i.e. was a multiple comparison test used such as least significant 
difference (LSD), or Tukey’s Test? This should be explained in the statistics sections 
and specified in the figure and table legends whenever multiple superscripts are used to 
denote differences. 
Response: Means have been separated by using least significant difference (LSD) 
procedures and statistical significance was accepted at p<0.05. I have employed this 
method to separate the means in figures or tables in Chapters 4; 5; 7 and 8. Therefore 
in sections 4.2.5; 5.2.6; 7.2.5 and 8.2.4 headed ‘Statistical analysis’, I have included the 
following sentence: “Where appropriate, means were separated using the least 
significant difference (LSD) procedures and statistical significance was accepted at 
P<0.05.” 
 
Comment 26: p62. I think it is stretching the imagination/misleading to state that the 
relationship between RAC and ADG was linear (even if linear equation was fitted to the 
data), as the effect of RAC shows a distinct plateau in light and medium pigs according 
to Fig 4.1. 
Response: The main effects of initial live weight and RAC dose are presented in 
Table 4.2. The main effect of RAC dose on ADG is significant (p=0.023). Inspecting the 
ADG closer one notes that as RAC dose increases ADG increases, therefore checking 
for a linear relationship between RAC and ADG is very relevant as the relationship has 
been reported in early studies (see discussion, section 4.4.1). It is not misleading to 
state that the relationship between RAC and ADG is linear and this is supported by the 
strong probability value attached to the relationship (P=0.006). As there were no 
significant dietary RAC x initial weight interactions in Experiment 1 (Gilts) there was 
no need to separate out the initial start weights for each RAC dosage levels as 
presented in Fig 4.1. However I did this because of the commercial relevance, to 
indicate graphically that responses to dietary RAC for ADG occur across all initial 
start weights.  
 
Comment 27: p68. In section 4.3.3. modify last sentence which currently reads “… at 
different conducted.” 
Response: Last sentence has been altered to read: “As both experiments were 
conducted separately and only included one sex, PUN values cannot be compared 
between sexes.” 
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Comment 29: Discussion, Section 4.4. The discussion would benefit from more critical 
analysis in terms of providing possible reasons why the current results were not those 
expected or not consistent with some earlier reports: 
a. In particular there is no discussion on the strengths and weaknesses of the 
experimental design 
b. Discuss the likelihood that there was no real difference between light medium 
and heavy weight boars in ADG. The response to RAC of medium pigs? 
c. Given the amount of variation in this initial experiment, it is surprising that the 
subsequent studies were not designed with fewer treatment combinations and 
more replicates to ensure more robust conclusions. 
Response: Part a. and b. I have included the following as the second paragraph in 
the Discussion section 4.4: “It was unfortunate that the experimental design involved 
two separate experiments in succession with one sex per experiment, and only 8 
replicates per treatment, which reduced the power of the experiments. Therefore, a 
reasonable argument for the observed high growth rate exhibited by the 5 mg/kg light-
weight boars compared to control, 10 or 20 mg/kg groups may in fact be an anomaly, 
and the apparent lack of response to RAC by the medium start weight boars a 
consequence of their unusually fast ADG. However had each experiment included both 
sexes, the experiments could have been blocked by time and would have doubled the 
treatment size to 16 replicates and provided sufficient power to the study. Unfortunately 
combining boars and gilts into the one experiment was not possible due to their 
different source herds and disease status. Using the abbreviated equation described by 
Morris (1999) to determine approximate minimum replicate number required to achieve 
a significance between treatment means,  
n = 8 x (CV%)2 / (d%)2 
Where n = minimum number animals; CV% =  (standard deviation) / (mean) x 100 ; and d = expected 
difference between treatment and control as a percentage. 
 
and applying improvements in FCR of 8% and a coefficients of variation (CV) of 10% 
(Rikard-Bell et al., 2009a), a minimum of 12 replicates per treatment is calculated. 
However, it was argued that an analysis of the main effects would provide sufficient 
power to determine whether start weight (32 replicates per weight category) or RAC 
dosage level (24 replicates per dosage level) were factors that influence the magnitude 
of response to dietary RAC in finisher pigs.  
  
Response: Part c. The lessons learnt from the initial start weight x RAC dosage 
studies were incorporated into the lysine studies that followed. For example, both sexes 
were included in each lysine study that were blocked by time due to space allowances, 
and therefore increased the power of each study. Unfortunately as in many studies, I 
was having to compromise when designing each study. Referral to the unifying 
hypothesis enabled careful consideration, so whilst most studies were intricate in their 
factorial design, in all studies sufficient replication occurred when analysing main 
effects. 
 
Comment 30: p80 and p81. The introduction is presented in journal format. If the 
intended format of the thesis is ‘thesis by publication’ style and this is acceptable by the 
University, then this section can stand as is. 
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Response: The formatting of this thesis was done in consultation with my 
supervisors, Professors John Pluske and Frank Dunshea. The style of formatting 
adopted is one that allows for publication in peer-reviewed journals. 
 
Comment 32: p81. As the lysine content was modified by altering the total protein mix, 
it would be helpful to acknowledge that this may have altered the level of amino acids 
in the diet and to comment on whether any of these other amino acids could be limiting. 
Response: I have altered the following sentence in section 5.2.2, Experimental 
Animals and Diets, from: “The concentrations of dietary lysine were altered by 
changing the protein content of the diets through adjustments to the amount of wheat, 
soybean and tallow.”, to the following: “The concentrations of dietary lysine were 
altered by changing the protein content of the diets through adjustments to the amount 
of wheat, soybean and tallow and formulated based on an ideal pattern of amino 
acids.” This discussion negates further comment regarding whether any other amino 
acid could have been limiting. 
 
Comment 35: p88. Suggest a comment to be included about why the gilts fed the high 
lysine diet appeared to grow more slowly than the gilts fed a low lysine diet. Was this 
difference real, and if so, what physiological explanation could there be? Or was it a 
likely artefact caused by too few animals or an outlying observation? 
Response: I have altered the paragraph in section 5.3.1, Live phase results, from: 
“A sex by lysine interaction was observed for the period 0 to 14 days for ADG (P = 
0.038) such that boars fed high lysine diets grew more quickly than boars fed the low 
lysine diet, whereas gilts fed high-lysine diets grew more slowly than gilts fed low-lysine 
levels.”, to the following: “A sex by lysine interaction was observed for the period 0 to 
14 days for ADG (P = 0.038) such that boars fed high lysine diets grew more quickly 
than boars fed the low lysine diet (1375 and 1278 g/day respectively), whereas gilts fed 
high-lysine and low-lysine diets grew at a similar rate (1170 and 1210 g/day, 
respectively).  
 
This suggests that the difference is a real effect. Furthermore, I have discussed the 
lysine x sex interactions in the discussion of section 5.4.5, Increasing dietary lysine: 
“An interesting outcome of this study were the observed sex x lysine interactions for 
ADG and lean tissue deposition indicating that the current recommendation of 0.56 g 
available lysine / MJ DE may limit the potential response of the boar in these traits. The 
present study showed that the rate of lean tissue deposition was not affected by 
increasing available lysine levels in gilts, however, boars showed increased lean 
deposition with the high-lysine diet (Fig 3), indicating that boars have a greater 
propensity for lean tissue deposition than gilt.” 
 
Comment 37: p88. Paragraph 2 states that “over the study duration dietary RAC 
increased ADG” whereas Table 5.2 shows that ADG for the low lysine boars given 20 
mg/kg RAC (1291 g/day) was less than that observed for the control boars (1330g/day). 
Response: Paragraph 2 implies that I am discussing main effects, however because 
there is an interaction between lysine and dietary RAC in the first 0 to 7 days, for ADG 
and FE, I am prohibited in discussing main effects of dietary RAC. Therefore I have 
deleted the references to ADG and FE over the first 0 to 7 days. As there are no 
observed lysine x dietary RAC interactions over the 28 days, I can refer to the main 
effects of dietary RAC. Table 5.2 presents a further partitioning of the data, with 
probabilities of the main effects of Sex, RAC and Lysine and their respective 
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interactions. The examiner has highlighted a difference between two treatment means 
presented in Table 5.2. that are contrary to the probability of the main effects of dietary 
RAC. This is of course possible, however the main effect of dietary RAC in the 
population of pigs in the study presented was to increase ADG. However for greater 
clarity I have altered this paragraph to read as follows: “Over the study duration (0 to 
28 days) the main effects of dietary RAC improved daily gain (P=0.026, Table 5.2). 
Additionally, as dosage of dietary RAC increased the ADG increased in a linear 
(P=0.072) and a quadratic (P=0.041) manner. However, FE was not altered (P=0.555) 
over the 28-day period. Further analysis of these data indicated there was a linear 
response for increased FE in the first 21-day period (P=0.015) (data not shown) with 
increasing levels of dietary RAC.” 
 
Comment 38: p95. Stating that fat deposition was reduced by RAC in a quadratic 
manner (which implies a reduction leading to a nadir or low point) is misleading, when 
data show an apparent increase, then a decrease relative to controls. There is the 
likelihood that no real effect occurred here, and again the experiment might have 
suffered from a lack of statistical power. 
Response: I agree with the comment, and I am only reporting the results in this 
section. To address the issue that there may be no real effect of dietary RAC on adipose 
tissue deposition rate due to lack of statistical power, I have altered the following 
sentences in the discussion, section 5.4.4 Dietary RAC and adipose tissue, from: 
“Although fat tissue deposition as determined by DXA did not show a reduction after 14 
days of treatment for RAC-fed pigs, fat tissue tended to be reduced (P = 0.074, 
quadratic) in the 20 mg/kg RAC-fed pigs after 28 days.”, to the following: “Although 
fat tissue deposition as determined by DXA did not show a reduction after 14 days of 
treatment for RAC-fed pigs, fat tissue tended to be reduced (P = 0.074, quadratic) in the 
20 mg/kg RAC-fed pigs after 28 days compared to the control pigs. Although the fat 
tissue deposition rate of the 20 mg/kg RAC treatment group supports the corresponding 
carcass data, the DXA data is reporting the results of only 3 pigs per treatment and 
hence interpretation of the result needs to be treated with some caution.” 
 
Comment 39: p96. The following statement needs to be qualified “the study confirmed 
that increasing RAC dose improves FE and ADG in a linear manner” e.g. focusing on 
the high lysine groups, ADG does not appear to be linear with RAC during any of the 3 
periods for either boars or gilts. 
Response: I have qualified this statement by referring specifically to the main 
effects of dietary RAC on FE and ADG after 21 and 28 day respectively, and as such I 
have altered the following sentence in section 5.4.1, Dietary RAC and ADG, FE and 
ADFI, from: “The study presented confirmed earlier observations that increasing RAC 
dose improves FE and ADG in pigs in a linear manner”, to the following: “This study 
reported that the main effects of dietary RAC improved FE and ADG and that 
increasing RAC dose improved FE and ADG in pigs in a linear manner after 21 and 28 
days respectively, confirming the observations of earlier studies.” 
 
Comment 42: p99. Having a greater sensitivity to β-adrenoceptor agonists, or a 
different density of β-adrenoceptors is not a plausible explanation for why down 
regulation would be delayed. 
Response: Yes, I would concur. Firstly, this sentence does not make sense and I 
have changed the sentence in section 5.4.4, Dietary RAC and adipose tissue, from: 
“Dunshea et al. (2009) proposed several plausible reasons for this delay in down 
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regulation.”, to read as follows: “Dunshea et al. (2009) proposed several plausible 
reasons for the observed reduction in the rate of fat deposition in the presence of 
dietary RAC.” 
 
Comment 42 ctd: p99. The discussion about the different responsiveness of adipose 
tissue in the pigs over time to dietary RAC is focussed entirely on receptor numbers, 
which are not measured here. Although this is an important aspect, it is disappointing 
that other concepts such as potency, intrinsic activity and efficacy, and the factors that 
influence these, are not mentioned. 
Response:  I would agree there is a strong focus on receptor numbers in the 
discussion, and the reason for this was because the study had been designed to measure 
the β-andrenoceptor gene expression in fat and muscle tissue (Chapter 8). I would also 
argue that I did discuss potency as the following sentence in the same paragraph 
indicates: “Second, the use of lower doses of RAC than used in the 1990s (5 or 10 
mg/kg versus 20 mg/kg) may delay the down regulation of β-adrenoceptors, allowing 
the expression of a reduction in fat deposition.” 
Moreover, and as this thesis is presented in the format of “thesis by publication” and 
this chapter has now been published in Animal Production Science, I would propose 
that the argument suggested by the examiner not be included as it is out of the scope of 
this chapter. I have also addressed other factors such as age and gender throughout the 
thesis. I would point out that sex x RAC interactions were not observed in this chapter, 
and therefore I see no reason to put forward this as a possible factor. 
 
Comment 43: p101. The conclusion is inaccurate (see comment 39 about ADG) 
Response: I have qualified this conclusion in comment 39 above, and I have 
therefore not altered this conclusion. 
 
Comment 45: p113. The statements concerning the critical level of lysine in gilts fed 5 
and 10 mg RAC are confusing and appear contradictory. If the critical lysine level for 5 
mg RAC was 0.51, and the level for 10 mg RAC was 0.50, then 10 mg did not increase 
the critical lysine level. 
Response: I have altered the following sentence from: “The 10 mg/kg RAC diet 
resulted in higher critical lysine levels compared to 5 mg/kg RAC diet of 0.50 and 0.52g 
available lysine/MJ DE for ADG and FCR respectively.”, to the following: “The 10 
mg/kg RAC diet resulted in similar critical lysine levels when compared to 5 mg/kg RAC 
diet of 0.50 and 0.52g available lysine/MJ DE for ADG and FCR respectively.” 
 
Comment 45 ctd: Similarly, the statement concerning boars that “higher critical lysine 
levels of 0.56 versus 0.65 versus 0.65 and 0.54 versus 0.59 appears to be nonsense. 
Response: I appreciate the examiner’s confusion, however I found this section difficult 
to write clearly and succinctly.. I have therefore rewritten the following paragraph: 
“The boars offered the higher level RAC diet of 10 mg/kg had improved response 
plateaus for ADG and FCR compared to boars fed the 5 mg/kg RAC diet, however, the 
improvements required higher critical lysine levels of 0.56 versus 0.65 and 0.54 versus 
0.59 g avail Lysine/MJ DE for ADG and FCR respectively.”, to the following: “The 
boars offered the higher level RAC diet of 10 mg/kg had improved response plateaus for 
ADG and FCR compared to boars fed the 5 mg/kg RAC diet, however the improvements 
required higher critical lysine levels. For example, in order to support the elevated 
responses observed when dietary RAC increased from 5 to 10 mg/kg, the critical lysine 
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levels needed to increase from 0.56 to 0.65 g available lysine with respect to ADG and 
from 0.54 to 0.59 g available lysine with respect to FCR.” 
 
Comment 46: p114. The figure legend is difficult to read. Formatting issue with graphs 
in this chapter. 
Response: Legends have been reformatted. 
 
Comment 47: p114. For this figure and several more the Y axis does not start at zero. 
This has the effect of exaggerating any difference between the treatment groups. While 
it can make a genuine difference more visible, it can also mislead the reader into 
believing there was a real difference when in fact the data just show random variation. I 
recommend reformatting all figures using a range commencing at 0.  
Response: In this instance I do not agree with the examiner’s comments. The range 
of the Y-axis has been selected to make a genuine difference visible. I would refer the 
examiner to King et al. (2000), Mullan et al. (2011), and Dunshea et al. (2009) in which 
similar graphs are presented with the Y-axis not starting at zero. In all cases the range 
of the Y-axis has been selected to make genuine differences more visible. 
 
Comment 48: p116. The results for 5 mg RAC at 0.64 g lysine do not seem to fit a 
logical pattern in boars. This suggests the presence of random variation caused by the 
undue influence of one or more outlying observations, again calling into question the 
power of the experimental design, which deserves some comment in the discussion. 
Response: I have included the following comment in the discussion section 6.4.3, 
Supplementation with dietary RAC: “The lack of response observed for boars fed 5 
mg/kg RAC diet at 0.64 and 0.72 g available lysine were not as expected. A more 
logical response pattern to dietary RAC would have shown a continuance of 
improvement at these higher dietary lysine levels. These results can most likely be 
explained due to the random variation exhibited by the small number of 9 replicates per 
treatment group” 
  
Comment 49: p123. This page summarises the results nicely, but presents no critical 
analysis or any reference to other findings. 
Response: I have left this page as presented to the examiner. The introduction to the 
discussion was intended to briefly summarise the results of the study. I then critically 
addressed each of the major discussion points: increasing lysine, sex differences and 
supplementation with dietary RAC using references where appropriate. This chapter 
has been recently published in the journal Animal Production Science. 
 
Comment 50: p124. The Rikard-Bell citation should refer to an earlier chapter of the 
thesis rather than a paper “submitted for publication” 
Response: The citation has been deleted and replaced with “In Chapter 5 it was 
found that …” 
 
Comment 51: p125. I disagree with the statement that RAC supplementation increased 
ADG linearly in gilts. The statement that “Pigs fed the higher lysine diets only 
responded to the higher RAC diets” is also misleading. 
It should be pointed out that the ADG response of gilts to RAC was equally good at 5 
and 10 mg/kg up to 0.56 g lysine (hence this is not a linear response), and that the 
response at 0.56g lysine was in fact equal to the response seen at the highest level of 
0.72 g lysine. 
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Response: The statement does not refer to gilts per se, but to both sexes and is 
drawn from Table 6.2 which indicates that as dietary RAC levels increase then ADG 
increases in gilts and boars; in this case, the linear relationship is supported by the p-
value of 0.001. What is interesting in the analysis in Table 6.2 is the effect of increasing 
lysine on ADG, which shows not only a strong linear relationship (P<0.001) indicating 
that as dietary lysine increases ADG increases, but also a quadratic relationship 
(P=0.001). The presence of the quadratic relationship suggests that as dietary lysine 
increases the incremental increases in ADG become smaller (in gilts), whilst the linear 
relationship is probably more influenced by the boar responses. 
 
To incorporate the suggestions of the examiner and for better clarity I have changed the 
first paragraph in section 6.4.3 from: “Supplementation of diets with increasing levels 
of RAC increased ADG and FCR linearly (P=0.001 and P=0.002, respectively) and did 
not affect VFI (P=0.333), which is in agreement with previous studies conducted at the 
same research institute (Rikard-Bell et al., 2007; Rikard-Bell et al., 2009d). Pigs fed the 
high lysine diets of 0.64 and 0.72 g available lysine/MJ DE only responded to the 
higher RAC diets, which is in agreement with the study of Webster et al. (2002)…”, to 
the following: “Supplementation of diets with increasing levels of RAC increased ADG 
and FCR linearly (P=0.001 and P=0.002, respectively) and did not affect VFI 
(P=0.333) of the pigs in this experiment, which is in agreement with previous studies 
conducted at the same research institute (Rikard-Bell et al., 2007; Rikard-Bell et al., 
2009d). However, the ADG response of gilts to RAC was similar at 5 and 10 mg/kg for 
the lower lysine diets of 0.40, 0.48 and 0.56g available lysine / MJ of DE, and therefore 
not suggestive of a linear response to dietary RAC. The lack of response observed for 
boars fed 5 mg/kg RAC diet at 0.64 and 0.72 g available lysine were not expected. A 
more logical response pattern to dietary RAC would have shown a continuance of 
improvement at these higher dietary lysine levels. These results are most likely be 
explained due to the random variation exhibited by the small number of replicates 
(n=9)  per treatment group. However, it is intriguing that gilts also exhibited a similar 
response when fed the 5 mg/kg diet which may highlight a dietary issue, although RAC 
and lysine levels were within specification for these diets. Pigs fed the high lysine diets 
of 0.64 and 0.72 g available lysine/MJ DE only responded to the higher RAC diets, 
which is in agreement with the study of Webster et al. (2002)” 
 
Comment 52:  p126. The notion that a higher RAC dose “stimulated a greater 
availability of β-adrenoceptors” is a radical one, even if there are data to support this. 
Although glucocorticoids are known to cause upregulation of their own receptors, as far 
as I am aware this is contrary to the observed effects of β-adrenoceptor agonists in every 
other system or species and should be acknowledged as such. 
Response:  I have inserted the following sentence after the proposal of the notion: 
“This notion, however, is speculative and is contrary to the observed effects of β-
adrenoceptor agonists in swine (Spurlock et al., 1994).” 
 
Comment 54: p126. The statement that “β1-AR may play an agonist or an antagonist 
role” is confusing as the terms agonist and antagonist refer to the properties of a drug 
not a receptor. 
Response: This was an oversight, and the sentence has been corrected to read: 
“Therefore, depending on dietary RAC concentration, RAC may play the role of an 
agonist or antagonist”. 
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Comment 54 ctd: More likely explanations for the larger response caused by the 10 
mg/kg RAC is that the higher dose caused a stronger stimulus by occupying more 
receptors, compensating for any desensitizing effect of RAC; showed less β1/β2 sub-
type specificity and stimulated both types of receptors; or that the pigs were less able to 
metabolize or excrete the higher dose. 
Response: I have included these more likely suggestions in section 6.4.3, 
Supplementation with dietary RAC. 
 
Comment 57:  p138. Specify means separation test. 
Response: See response to comment 25. 
 
Comment 58: p140, 145. Suggest modifying the stated objective. The experimental 
design allowed the author to test if the response to pST plus RAC was greater than the 
response to RAC alone. However, by excluding a ‘pST alone’ group the design did not 
allow him to determine if the response to pST and RAC was additive. In theory the 
response to the combined treatment could have been all due to pST. 
Response: The experiment was able to measure the additive effect of pST+RAC 
because the comparison was made to a RAC treatment and a control treatment. I do 
agree that without the ‘pST alone’ treatment I was not able to account for the pST effect 
without RAC, which I have discussed as a limitation in section 7.4.  
 
The application of pST was in the final 2 weeks of the treatment regimens, and I am 
therefore able to observe the dietary RAC response in the initial 2 weeks, followed by 
dietary RAC ‘with pST’ or ‘without pST’  for the final two weeks. To that extent I am 
able to comment on the additive effects of pST to a RAC regimen. I therefore have not 
modified the stated objective. 
 
Comment 59: p142. The statement that pST is dose responsive is curious. In theory, all 
drugs that act through specific receptors should demonstrate a dose-response 
relationship, obeying the principles of binding kinetics. 
Response: I wanted to make the statement that studies have been conducted to show 
the dose response nature of pST, and that the low dose used in the experiment may have 
contributed to the small responses observed. In order to improve clarity I have added 
the following sentence to begin the paragraph: “Beermann et al. (1990) reported that 
pST increases skeletal muscle mass by muscle fibre hypertrophy and reduces muscle 
lipid concentration in a dose dependent manner. In general, my results have smaller 
responses to pST with respects to lean deposition rates when compared to the 
literature.” 
 
Comment 60: p143. The term β-cell receptors is used several times instead of β-
adrenoceptors.  
Response: All amendments have been made. 
 
Comment 61: p144. The discussion of possible interactions between pST and RAC is a 
little superficial and missing several key references such as Etherton and Walton, 1986; 
Watt, 1991 and Sillence, 2002. 
Response: I have included in the discussion section 7.4, Interactions between pST 
and RAC, and cited the key references. I have changed the original sentences from: 
“These results are typical of those cited in the literature (Campbell et al., 1991; 
Campbell et al., 1989; King et al., 2000). Likewise the addition of pST to RAC-treated 
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pigs markedly reduced delta P2 back fat readings. This study also observed that in the 
final 14 days, dietary RAC also reduced the expected increase in P2 in boars 
(P<0.05).”, to the following: “These results are typical of those cited in the literature 
(Campbell et al., 1991; Campbell et al., 1989; King et al., 2000). Likewise the addition 
of pST to RAC-treated pigs markedly reduced delta P2 back fat readings. It is possible 
that in the study presented the lipolytic effects of RAC are enhanced by the co-
administration of pST. This is consistent with the observation that growth hormone has 
no direct lipolytic action in porcine adipose tissue, but increases the tissue’s 
catecholamine sensitivity (Etherton and Walton, 1986). Sillence et al. (2002) confirmed 
that growth hormone can attenuate the down regulation of β-adrenoceptors, seen in 
pigs treated with the β2-adrenoceptor agonist clenbuterol.” 
 
Comment 62: p147. Part 2 of this chapter presents a separate experiment with different 
aims to the experiment described in part 1. It is not clear why this is not presented as a 
separate chapter. 
Response: Part 1 and Part 2 of Chapter 7 refer to the two combination studies. In 
consultation with Professor John Pluske I decided to report the studies separately but 
under one chapter, as both technologies are metabolic modifiers and are used in 
combination with dietary RAC in the Australian pig industry.  
 
Comment 64: p152. All previous chapters have reported FCE values, whereas G:F 
values are reported here. This is doubtless due the requirements of the Journal of 
Animal Science, but altering the terminology here hinders comparisons with earlier data 
and disrupts the cohesiveness of the thesis. 
Response: I do agree. However, I would respectively request that the paper(s) 
remains as presented. My argument is that I requested to my supervisors Professor 
John Pluske and Professor Frank Dunshea that I would like to submit this thesis in the 
format of “Thesis by publication” with the intention of publishing in several journals. 
Unfortunately in doing so one has to follow the requirements of the specific journal. I 
believe this is an excellent way to present a thesis because the student becomes skilled 
in the practice of scientific writing whilst preparing the thesis. I would like to point out 
that the Journal of Animal Science requires reporting of G:F (Chapter 7), whereas 
Animal Production Science is satisfied with FE (Chapter 5); both are the same ratio. In 
all other chapters I have reported FCR.  
 
Comment 65: p164. β-adrenoceptors feature heavily throughout the thesis, yet the 
abbreviation β-AR is not introduced until chapter 8. For consistency and cohesiveness 
in presentation this needs to be amended. 
Response: I have introduced the abbreviation when the term β-adrenoceptor is first 
used in each chapter. 
  
Comment 67: p164. There are a few illogical statements. “ligand binding studies 
provide little evidence for functional receptors of the β3 sub-type” 
 
a. Ligand binding studies are not intended to identify functional receptors by their 
nature – only the presence of specific binding. 
b. “Gunawan et al were not able to detect β3-AR in muscle and concluded that β3 
were expressed at undetectable levels” If they were not detected, what evidence 
is there that they were expressed at all? 
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Response: part a: I have deleted the word “functional”; part b: This was a direct 
quote from the paper by Gunawan et al. However, I have altered the sentence to read as 
follows: “Recently, Gunawan et al. (2007) did not detect β3-AR in porcine skeletal 
muscle using real-time PCR and the primer was specifically designed to porcine 
sequences.” I wanted to cite the result obtained by Gunawan et al. because I was not 
able to observe β3-AR gene expression in adipose or muscle tissue using PCR 
techniques. 
 
Comment 69: Chapter 9. No experiment is perfect and the chapter would be improved 
by acknowledgement or insight into the weaknesses inherent in the research in terms of 
experimental design, housing conditions, availability of pigs etc as well as some 
recommendations on how the methodology could be improved for future studies. 
9.1 Response: I have added the following to Chapter 9: “Weaknesses of this 
thesis 
 
The weaknesses of this thesis in my opinion were as follows: 
 
I. The dose response studies were conducted as separate studies for boars and gilts. 
This reduced the power of the study, as I was not able to compare interactions 
between sex and dosage rate. However, in later studies I was able to include sex as 
a factor and determine sex x RAC dose interactions. 
II. The current gene expression data set and the corresponding DXA scan information 
only allows me to comment on effects at day 15, the first data point post-treatment. 
The greatest response to dietary RAC is within the first week. Animal numbers, and 
limitations of space in the finisher test station, restricted the number of data points. 
In particular DXA scans and tissue biopsies at Day 7 to coincide with live animal 
measurements would have been useful as there were RAC x lysine interactions for 
day 0-7 data.  
III. The combination study involving porcine somatotropin and dietary RAC ideally 
should have included an additional treatment of pST without dietary RAC. 
However, availability of animals and space within the testing station influenced the 
experimental design. It has also been acknowledged, for the traits measured, that  
statistical significance (p<0.05) for differences in treatment means may not have 
occurred due to a low number of replicates per treatment.  
IV. The combination study involving boars immunized against GnRF did not have an 
acclimatisation period prior to commencement of treatment. The taking of 
measurements, allocation to treatment, and mixing of pigs on Day 0 may have 
affected responses to treatment. Additionally and due to pen numbers, I was 
restricted on treatment number, and therefore a straight 5 mg/kg RAC treatment 
was not included.  
V. The incorporation of DXA scan measurements for the lysine titration study would 
have enabled measuring grams of available lysine/gram of tissue accretion in boars 
and gilts with or without dietary RAC. However, the logistics of transporting and 
handling carcasses and the related costs prevented incorporation of DXA scanning 
into this experiment.  
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Specific Comments  
 
Examiner:  Professor Gary Allee 
I would like to thank Professor Gary Allee for his comments regarding this thesis. 
 
Comment: The information in this dissertation would be more valuable to the 
Australian pig industry if there were an economic appraisal of dose and duration of 
RAC feeding and lysine levels 
Response: Whilst I would agree with this comment it is out of the scope of this 
dissertation. 
 
Comment: How does dietary lysine level with RAC change in group housed pigs? 
Response: Interestingly the lysine titration study reported in this dissertation 
(Chapter 6) was extended to a group housed environment. Mullan et al (2011) reported 
that ADG in finisher gilts began to plateau at 0.56 g available lysine/MJ of  DE, which 
was similar to the controls in chapter 6. However with the addition of dietary RAC the 
finisher gilts continued to respond with increasing dietary lysine levels up to 0.72 g 
available lysine. Mullan et al concluded that higher levels than 0.56g available lysine / 
MJ of DE are  required to maximize performance in finisher gilts supplemented with 
dietary RAC. Similar to the individual pen study Mullan et al (2011) also reported 
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SUMMARY 
The series of experiments presented in this dissertation were conducted to 
evaluate the optimal responses to dietary RAC in the Australian pig industry. The 
unifying hypothesis was proposed in two parts: first, optimal responses to dietary 
ractopamine (RAC) depends on factors that include the level of dietary lysine, level of 
dietary RAC and gender, whilst the inclusion of specific metabolic modifiers porcine 
somatatropin (pST) and anti-GnRF immunization vaccine (Improvac) has synergistic 
effects on growth and performance. Second, the β-adrenoceptors (β) in adipose and 
skeletal muscle respond differently to RAC dose and therefore the down regulation of 
specific βs mediates the responses observed in fat and muscle tissue deposition rates. 
 Experiment 1 (Chapter 3) was  conducted to compare current commercial 
applications of dietary RAC and dietary RAC+pST and their responses in growth 
performance as well as lean and fat tissue deposition at day 0, 14 and 28 in boars, gilts 
and boars immunized against GnRF. The study was also designed to confirm whether 
RAC decreases fat deposition in boars and boars immunized against GnRF. The results 
of Experiment 1 were surprising in the fact dietary RAC  and RAC+pST had no effect 
on average daily gain (ADG) (P=0.543) or feed conversion ratio (FCR) (P=0.255) on 
these fast-growing, high-health-status finishing pigs. The effect of dietary RAC on 
tissue deposition rates were also unexpected as a reduction in fat deposition rate 
occurred (P=0.064) but no effect on lean deposition rate was observed (P=0.642). The 
results of experiment 1 influenced the design of the experiments that followed in which 
factors that affect responses in production and tissue deposition responses to dietary 
RAC were examined.  
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Experiment 2 (Chapter 4) comprised of  two RAC dose studies to determine the 
response in light, medium and heavy initial-weight gilts (study 1) or boars (study 2) fed 
four levels of dietary RAC (0, 5, 10, and 20mg/kg) over a 28-day feeding regime. The 
hypothesis examined was that light, medium and heavy initial-weight pigs have similar 
responses to increasing levels of dietary RAC. The major findings were: 
In gilts for all initial weight categories: 
• Dietary RAC improved ADG, FCR compared to controls (P=0.023 and P=0.029, 
respectively). 
• A linear relationship was observed for ADG (P=0.006) and FCR (P=0.003) with 
increasing dose of RAC  
• Carcass weights improved linearly (P linear =0.006) and tended to improve 
dressing percentage (P=0.098) with increasing dose of dietary RAC,  and  
In boars for all initial weight categories, 
• Incremental increases of RAC resulted in linear increases for ADG (P=0.003), 
HSCW (P=0.018) and dressing percentage (P=0.045). 
• Dietary RAC did not alter FCR (P=0.289), however there was a tendency 
(P=0.082) for FCR to decrease linearly as dosage level of dietary RAC increased.  
 
 Experiment 3 (Chapter 5) was conducted to investigate whether there are 
interactions between RAC dosage levels and two levels of dietary lysine (low and high, 
0.56 and 0.65 g of available lysine / MJ DE, respectively) on growth performance and 
carcass characteristics of finisher boars and gilts using dual energy X-ray 
absorptiometry (DXA) to measure body composition. The hypothesis examined was 
that low lysine diets of 0.56 g available lysine/MJ DE are sufficient to optimize the 
response in feed efficiency, growth rate and tissue deposition in boars and gilts fed high 
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(20 mg/kg) or low (5 mg/kg) levels of dietary RAC at initial weights of 65 kg. The 
major findings were: 
• There were significant interactions (P = 0.023 and P = 0.025) between dietary RAC 
and lysine levels in the first seven days for ADG and feed efficiency (FE) 
respectively, such that pigs fed high-lysine diets supplemented with dietary RAC had 
improved ADG and FE, whereas pigs fed low-lysine diets did not respond to RAC 
supplementation in the first seven days. 
• Over the study duration dietary RAC improved daily gain (P=0.026). 
• As RAC dose increased ADG  increased in a linear (P = 0.072) and a quadratic (P = 
0.041) manner.  
• In the first seven days dietary RAC improved FE (P = 0.002), but not over the study 
duration (P = 0.555).  
• Dietary RAC reduced change in P2 backfat (P=0.002) as well as indicating a linear 
(P = 0.033) and quadratic (P = 0.003) reduction with increasing dose in both boars 
and gilts over the duration of the study. 
• A lysine x sex interaction (P=0.043) indicated that lean deposition rate increased in 
boars but not gilts when fed the high lysine diet. 
•  Dietary RAC tended (P < 0.1) to increase lean deposition rate only in boars fed high 
lysine diets. 
• Dietary RAC tended to alter lean tissue deposition rates over the initial 14-day period 
(P = 0.067) and as RAC dose increased lean tissue deposition increased over 14 (P = 
0.035) and 28 days (P = 0.044).  
• Fat deposition tended to be reduced in a quadratic manner (P = 0.074) as dietary 
RAC increased over 28 days. 
Page| XXVI  
 
Experiment 4 (Chapter 6) was conducted to investigate the responses of finisher 
pigs offered a wider range of dietary lysine levels (0.40, 0.48, 0.56, 0.64 and 0.72 g 
available lysine/MJ DE) and three levels of dietary RAC (0, 5 and 10 mg/kg) over 28 
days duration, to determine the optimal level (critical value) of dietary lysine with or 
without RAC, after which the response to increasing dietary lysine is insignificant in 
male and female finisher pigs. The major findings were: 
• The critical value of dietary lysine for gilts without RAC supplementation for ADG 
and FCR was 0.54 and 0.52 g available lysine/MJ DE, respectively. 
• The critical value of dietary lysine for gilts offered 5 mg/kg RAC supplementation 
for ADG and FCR was 0.51  and 0.49 g available lysine/MJ DE, respectively. 
Increasing RAC supplementation to 10 mg/kg increased the critical values to 0.51 
and 0.52 g available lysine/MJ DE for ADG and FCR respectively 
• A response plateau was not calculated for control boars because the data set did not 
display diminishing responses for ADG or FCR over the range of dietary lysine 
concentrations offered. 
• Boars offered the 10 mg/kg RAC diet had improved response plateaus for ADG and 
FCR compared to boars fed the 5 mg/kg RAC diet, however, the improvements 
required higher critical lysine levels of 0.65 versus 0.56 and 0.59 versus 0.54 g avail 
Lysine/MJ DE for ADG and FCR respectively.   
 
Experiment 5 (Chapter 7) consisted of two combination studies. The first study 
examined the combination of dietary RAC and porcine somatatropin (pST) and the 
second study examined the effect of anti-GnRF immunisation vaccine (Improvac) and 
dietary RAC. The hypothesis tested for the first study was that the combination of a 28-
day dietary RAC regimen with the addition of daily injections of pST in the final 14 
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days will have additive effects on pig performance when compared to a 28 day dietary 
RAC regimen. The major findings were: 
• Over the study duration FCR was reduced by the RAC + pST treatment (P<0.05) and 
tended (P<0.09) to be reduced by the RAC only treatment. 
• The ADG of the RAC and the RAC+pST treated gilts increased (P<0.05) compared 
to the control gilts, whereas the ADG of the treated boars did not differ from control 
boars (Treatment x sex interaction, P=0.025) 
• In the second half of the study both dietary RAC and the combination treatments 
increased (P<0.001) lean tissue deposition in gilts by 165 and 286 g/day respectively. 
• The RAC + pST treatment increased lean tissue deposition in boars by 202 g/day 
when compared to respective controls. 
• The RAC + pST treatment also reduced (P<0.001) fat tissue deposition by 87 g/day 
(gilts) and 118 g/day (boars) when compared to controls in the final 14 days. 
• The dietary RAC treatment did not alter fat deposition significantly in gilts and 
boars. 
The hypotheses to be tested for the second study were that 1) anti-GnRF 
immunization would increase average daily feed intake (ADFI) around 2 wk after 
secondary vaccination, and that 2) a simultaneous step-up in dietary RAC concentration 
would allow the additional energy intake to be deposited as lean tissue rather than fat. 
The major findings were: 
• Boars immunized against GnRF had greater ADG and ADFI, but a reduced 
Gain:Feed (G:F) than the entire boars (P<0.001) over the study duration.  
• Pigs fed RAC had greater ADG and Gain:Feed (G:F) (P< 0.001) and tended to eat 
less (P<0.076) than the controls.  
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• The change in ultrasound P2 backfat during the study was greater (P<0.001) in boars 
immunized against GnRF and tended to be reduced (P=0.076) by RAC in boars 
immuniszed against GnRF. 
• Percent lean in the half carcass was increased (P=0.006) by dietary RAC, conversely, 
percent fat in the half carcass was decreased (P=0.004) by dietary RAC.   
Experiment 6 (Chapter 8) was conducted to examine the β gene expression using 
PCR techniques in adipose and skeletal muscle tissues of boars and gilts fed dietary 
RAC at either a low (5 mg/kg) or high (20 mg/kg) level compared to control pigs fed (0 
mg/kg RAC)..  The pigs used in this study were from Experiment 3. The hypotheses 
was that adipose and skeletal muscle tissue respond differently to dose level of RAC 
with respects to down (or up) regulation (as measured by the abundance of mRNA 
transcripts) of the specific βs in finisher boars and gilts. The major findings were: 
Within adipose tissue: 
• The β1-AR gene was not affected by duration of treatment (P=0.88) or sex (P=0.54), 
however the addition of dietary RAC reduced the expression  (P=0.04). 
• The β2-AR gene was not affected by dietary RAC (P=0.66), or sex (P=0.22), 
however day of treatment increased β2-AR expression at day 29 of treatment 
compared to day 15 (P=0.06). 
Within skeletal muscle tissue: 
• The β1-AR gene was not affected by sex  (P=0.43) or day of the study (P=0.69) but 
increased expression with the addition of dietary RAC (P=0.04). 
• A sex x RAC dose x Day interaction was observed (P=0.12). Only the boars fed the 
low RAC diet increased β1-AR expression at day 15 whereas gilts fed high RAC at 
Page| XXIX  
 
day 15 and the low RAC at day 29 had increased β1-AR expression compared to 
controls. 
• A sex effect was observed for β2-AR expression (P=0.05), in that the control gilts 
had a greater expression of the β2-AR gene after 29 days than control boars. 
• The addition of dietary RAC tended to reduce the expression of the β2-AR gene 
(P=0.07) particularly at the high inclusion level (20 mg/kg) of dietary RAC. 
 
From the results obtained in this thesis, I conclude that:  
1. RAC dose rates are effective in improving production indices and carcass traits in 
light (65 kg), medium (80 kg) and heavy (95 kg) initial-weight boars or gilts.  
2. Dietary lysine levels are critical in the first 7 days of the dietary RAC regimen. 
3. The lysine requirements for boars are higher than gilts between 65 and 95 kg live 
weight in order to maximise growth and lean tissue deposition. 
4. The combination of pST in the final 14 days of a 28-day RAC feeding regime was 
synergistic in gilts for FCR, ADG and lean deposition, whereas boars further 
declined their P2 backfat levels with the addition of pST. 
5. The additional growth in boars immunized against GnRF was as fat tissue, and that 
this could be attenuated by supplemental dietary RAC. 
6. The β2-AR has a more critical role as the age of the finisher pig advances as 
expression of the gene increases over time whereas the β1-AR expression is constant. 
7. The β2-AR was less sensitive to dietary RAC in fat tissue than the β1-AR gene 
which down regulated independent of RAC dose at day 15 and may explain the 
lipolytic response observed in Experiment 3, Chapter 5.  
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8. The down regulation of β2-AR expression observed in muscle by pigs treated with 
RAC suggested that the β2-AR may mediate the decline in response observed for 
ADG (8.6% to 3.7%) and FE (7.1% to 5.8%) in Chapter 5.  
9. Low level of dietary RAC has a stimulatory effect on the expression of the β1-AR 
gene. The up regulation of β1-AR may explain why only small differences between 
responses in lean meat deposition rates occurred for pigs fed either a high (20 mg/kg) 
or low (5 mg/kg) RAC diet.  
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